New Agents For Egfr Nsclc Osimertinib And Beyond Vjoncology

By hairstyler On Nov 21, 2025

New Agents For EGFR+ NSCLC: Osimertinib And Beyond - VJOncology

New Agents For EGFR+ NSCLC: Osimertinib And Beyond - VJOncology Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment

EGFR+ Lung Cancer: Going Beyond Osimertinib | Navigating EGFR

EGFR+ Lung Cancer: Going Beyond Osimertinib | Navigating EGFR (Barcelona, Spain September 6, 2025, 5:45 pm CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges Traditional HUTCHMED announced significant findings from the SACHI Phase III study, which investigated the combination of savolitinib and osimertinib in treating patients with locally advanced or metastatic EGFR

FDA Approves New Treatment Option: Osimertinib Plus Chemotherapy For ...

FDA Approves New Treatment Option: Osimertinib Plus Chemotherapy For ... Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges Traditional HUTCHMED announced significant findings from the SACHI Phase III study, which investigated the combination of savolitinib and osimertinib in treating patients with locally advanced or metastatic EGFR Dr Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations He discusses the new evidence for NSCLC with EGFR mutations and Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients

EGFR Mutant NSCLC Post Osimertinib | IASLC

EGFR Mutant NSCLC Post Osimertinib | IASLC Dr Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations He discusses the new evidence for NSCLC with EGFR mutations and Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients

Osimertinib + Ipilimumab In EGFR-mutated NSCLC - VJOncology